Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
RANKL Inhibitor — Monoclonal Antibody

Denosumab (Rheumatology — Osteoporosis)

Brand names: Prolia, Xgeva

This is denosumab used in rheumatology for osteoporosis — a subcutaneous monoclonal antibody given twice yearly to reduce fracture risk in postmenopausal women and others at high risk.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It binds and neutralises RANK ligand, preventing osteoclast formation and activity and thereby reducing bone resorption and increasing bone mineral density.

Prescribing in practice

  • Stopping treatment causes rapid loss of bone density and a rebound risk of multiple vertebral fractures, so doses must be given on time and alternative therapy planned if it is discontinued.
  • Correct hypocalcaemia before each dose and ensure adequate calcium and vitamin D intake, with caution in significant renal impairment.
  • Counsel on osteonecrosis of the jaw and atypical femoral fracture; for the osteoporosis indication use the lower-strength product per the SPC.

Monitoring

Check calcium before each injection, particularly in renal impairment, and review dental health and adherence to the dosing schedule.

Counselling the patient

  • Do not delay or stop injections without discussing follow-on treatment.
  • Take calcium and vitamin D as advised and report jaw pain or thigh pain.
  • Maintain good dental hygiene and report mouth problems.

Evidence & guidelines

Fracture-risk reduction in postmenopausal osteoporosis is demonstrated by a large randomised controlled trial.

Reference: FREEDOM Trial (NEJM 2009); MHRA DSU 2020 (hypocalcaemia); NICE TA204; NOGG Osteoporosis Guidelines; SPC Prolia; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Pathways